Shots:

• Sangamo provides an update on its pre/ clinical pipeline and emphasizes on its global capabilities across clinical science- operations- product development and manufacturing at its R&D day
• The company highlights the completion of IND transfer to Pfizer for its gene therapy candidate- SB-525 with the expected onset of its P-III study in 2020 by Pfizer. Sangamo also provides an overview of its engineered ex vivo cell therapies for beta-thalassemia- kidney transplantation and preclinical candidates for MS
• The company is targeting new gene therapy and genome regulation programs for clinical development with their expected IND submission in 2021 and 2022 for Alzheimer’s and Parkinson’s disease. It also reveals its CAR-_TREG clinical and preclinical programs

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Sangamo